June 3 (Reuters) - Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson, seeks to raise about $144 million in its initial public offering in the United States. (Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Shilpi Majumdar)